Skip to main content

Ciltacabtagene Autoleucel

(SIL-tuh-KAB-tuh-jeen AW-toh-LOO-sel)

This page contains brief information about ciltacabtagene autoleucel and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
Carvykti
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Ciltacabtagene autoleucel is approved to treat:

Ciltacabtagene autoleucel is only available as part of a special program called Carvykti REMS (Risk Evaluation and Mitigation Strategies).

More About Ciltacabtagene Autoleucel

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Research Results and Related Resources

Carvykti Approval Marks Second CAR T-Cell Therapy for Multiple Myeloma

Targeted Cancer Therapies

FDA Approves BCMA-Targeted CAR T-Cell Therapy for Multiple Myeloma

NCI Initiative Aims to Boost CAR T-Cell Therapy Clinical Trials

T-cell Transfer Therapy

CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers

Clinical Trials Accepting Patients

Find Clinical Trials for Ciltacabtagene Autoleucel - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: